Business UpdateJun 17, 2026, 08:48 AM
Ernexa ERNA-101 advances to clinic, IND planned Q3 2026, Phase 1 Q4
AI Summary
Ernexa Therapeutics announced significant progress for its lead oncology candidate, ERNA-101, with manufacturing process development completed and GMP production underway. The company plans to submit an Investigational New Drug (IND) application in Q3 2026 and initiate a first-in-human Phase 1 clinical study in Q4 2026 for platinum-resistant ovarian cancer. Preclinical data demonstrated compelling anti-tumor activity, especially in combination with PD-1 blockade. Ernexa also stated it has sufficient resources from a recent $10.5 million financing to support its near-term development strategy and anticipated milestones.
Key Highlights
- ERNA-101 Investigational New Drug (IND) submission planned for Q3 2026.
- First-in-human Phase 1 clinical study for ERNA-101 to begin in Q4 2026.
- Preclinical studies showed 100% long-term survival with ERNA-101 combined with PD-1 blockade.
- Recent $10.5 million financing provides sufficient resources for 12-18 months.
- First GMP clinical product batch release for ERNA-101 expected in Q3 2026.
- Initial clinical data from ERNA-101 Phase 1 study expected in H1 2027.
- Pre-IND meeting for ERNA-201 autoimmune disease program planned for Q4 2026.
Price Impact
More from ERNA